Pharma Fridays – December 22

December 22, 2023

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency On December 19, Ascendis Pharma announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Pharma Fridays

←Eureka 2023! Part IV: Top Endocrine Discoveries

Endocrine Society Applauds Ohio Governor Veto of State Ban on Gender-affirming Care for Minors→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today